Your browser doesn't support javascript.
loading
Understanding and integrating cytoreductive nephrectomy with immune checkpoint inhibitors in the management of metastatic RCC.
Das, Arighno; Shapiro, Daniel D; Craig, Juliana K; Abel, E Jason.
Afiliación
  • Das A; Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
  • Shapiro DD; Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
  • Craig JK; Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
  • Abel EJ; Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. abel@urology.wisc.edu.
Nat Rev Urol ; 20(11): 654-668, 2023 11.
Article en En | MEDLINE | ID: mdl-37400492
Cytoreductive nephrectomy became accepted as standard of care for selected patients with metastatic renal cell carcinoma (mRCC) because of improved survival observed in patients treated with cytoreductive nephrectomy in combination with interferon-α in two randomized clinical trials published in 2001. Over the past two decades, novel systemic therapies have shown higher treatment response rates and improved survival outcomes compared with interferon-α. During this rapid evolution of mRCC treatments, systemic therapies have been the primary focus of clinical trials. Results from multiple retrospective studies continue to suggest an overall survival benefit for selected patients treated with nephrectomy in combination with systemic mRCC treatments, with the notable exception of one debated clinical trial. The optimal timing for surgery is unknown, and proper patient selection remains crucial to improving surgical outcomes. As systemic therapies continue to evolve, clinicians have an increasing need to understand how to incorporate cytoreductive nephrectomy into the management of mRCC.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Neoplasias Renales Tipo de estudio: Clinical_trials / Observational_studies Límite: Humans Idioma: En Revista: Nat Rev Urol Asunto de la revista: UROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Neoplasias Renales Tipo de estudio: Clinical_trials / Observational_studies Límite: Humans Idioma: En Revista: Nat Rev Urol Asunto de la revista: UROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido